Seal strength tests on two laparoscopic instruments indicate that each offers separate advantages when sealing ureters and blood vessels, researchers reported at the World Congress of Endourology & SWL.
Shanghai, China-Seal strength tests on two laparoscopic instruments indicate that each offers separate advantages when sealing ureters and blood vessels, researchers reported at the World Congress of Endourology & SWL.
Clinically, the study findings serve as a guideline for surgeons who routinely use the two devices-the Harmonic ACE (Ethicon Endo-Surgery, Cincinnati) and the Ligasure V (Valleylab, Boulder, CO)-as adjuncts to standard monopolar electrosurgical instruments during the course of a laparoscopic procedure.
For the study, researchers from the University of California, Irvine, used a porcine model to seal multiple blood vessels and both ureters using each device. The burst pressure of the seals was tested, as were the seal time, seal quality, and the animals' serum albumin. The tissue was also submitted for histopathologic evaluation.
The Harmonic ACE appeared to cause a lower amount of subjective tissue damage than both one or two seals with the Ligasure V.
"In blood vessels, though some surgeons may seal the vessel twice when using the Ligasure V, this work suggests that one seal is better than a double seal.," said study co-author Michael Louie, MD, a clinical instructor in urology at the UC-Irvine, working with Ralph V. Clayman, MD, and colleagues.
As there appears to be more tissue effect when two seals are employed with the Ligasure V, one seal is the safer method, the researchers conclude. When considering the ureteral transection, both devices appear to be equally efficacious.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.